about
A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCRRituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study).Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups.SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis.Prevalence of Achromobacter xylosoxidans in pulmonary mucosa-associated lymphoid tissue lymphoma in different regions of Europe.5'UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia.RALE051: a novel established cell line of sporadic Burkitt lymphoma.Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia.Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.Adrenomedullin in the growth modulation and differentiation of acute myeloid leukemia cells.Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.Network integration of multi-tumour omics data suggests novel targeting strategiesInotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemiaNovel Agents for Acute Myeloid LeukemiaGrading of Neuroendocrine Carcinomas: Correlation of Ga-PET/CT Scan with Tissue BiomarkersEvaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitorsPrognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicinIdentification of a novel large EPCAM-MSH2 duplication, concurrently with LOHs in chromosome 20 and X, in a family with Lynch syndromeGilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AMLSynergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic LeukemiaPopulation Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid TumorsThe balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemiaIntrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective studyImpact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trialUnexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin?Leukemia cutis in a Ph+ ALL patient treated with ponatinibResponse of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genesNovel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid LeukemiaIdentification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid LeukemiaLong-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patientsNew generation anaplastic lymphoma kinase inhibitorsBlinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemiaProspective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML studyChronic myeloid leukemia stem cells
P50
Q35059443-1BF519F6-C402-4670-906A-8B0A4055B761Q35880154-2380F307-3934-4FFE-BABC-B5C9A89A174CQ36962747-04DB76E9-F5BF-493E-9996-0D8AD3579B08Q37644528-85B94470-3D6A-4C30-AC80-0FF12D235F19Q38588931-0966A7D2-50C8-47C1-AA18-5D52080B0364Q38698612-553A1CF9-D9B3-4D3F-92C4-CF893D61940FQ38778519-0849BC74-7C58-4877-83CB-7AACB8129AC1Q42234991-24627679-B9F6-4C35-A26E-55CA98844367Q42330009-6E0234AC-AE97-4C60-B905-EDE860CDEFA9Q42777641-12A6E481-CC34-4DBB-82C4-0A5E865AE25EQ45252214-BA19C2D7-A7F8-47A2-B5B8-D04E1F8D6AC9Q47326031-CDC86000-903E-468A-9716-E1759AE12008Q49888044-F0946DA3-A055-4005-926C-16D46C99BC86Q53183688-CA048D93-170E-4585-8DA3-C3B67829A87BQ54282700-B88755AD-D3BB-417A-BFCD-DE3A81F6D9CFQ58097633-FE77EB0F-F3B4-497C-BE4A-4C1D116D0607Q59337353-A806EA0B-700F-42CB-8A88-89947F1E8DBAQ59793137-E6205996-ACE6-49D1-AD5C-51331D8851F1Q60921527-E654460E-B2D1-4051-A2C1-147733A84837Q64116663-580B89E9-69E0-4404-B2BB-12B884C1BA9DQ64282259-FB1472CA-9BA4-4949-BF30-8FA571CF92DCQ90955287-51BF0998-5894-4DA2-A8E4-2A2AAFD44DE7Q90959078-AD894A3C-10B5-4968-9153-6BA8585A3594Q91007369-65541386-B333-42F7-85A4-8B4251D4F465Q91253678-36EB7A5E-4EB5-4FAC-B09E-05E258394B2FQ91457719-23115B6D-FEC0-47D2-8BFB-DEE8FA0AA2E5Q91471073-1C3A3112-C701-4057-B6A3-81238552617CQ91536117-A3F79521-6CEA-4EFB-BADE-48059BD93153Q91556007-8ABF7F44-0973-44ED-8D9E-2F15B7F0DE8AQ91608813-10599EAC-9894-4B14-B19C-A33CE862C5D0Q91625319-32983E49-9B9C-4401-B2B5-0D70F6774AEAQ91678474-5B05EB02-A9D6-4BF9-B905-9FDD471754BDQ91762994-5D0A840F-C5F7-4FDE-8242-81589F385DFCQ91812671-D8457F1D-1D0A-4482-B5CC-8AB710E11EF9Q91894415-088F551E-9FAB-4B79-99EF-2C80497E27F3Q92090061-0E2EE2E2-0E37-400E-840D-66D493D4C65BQ92134597-F82942A8-9CA3-4C2A-8A56-D44704685243Q92245197-29D7416A-2419-43FD-A681-5BA56EBDCF48Q92252507-B8F1D8F9-4870-4CF4-9A68-6CBE1BF29582Q92282773-A83DE941-EC69-413D-9157-305AFA26FD16
P50
description
researcher (ORCID 0000-0002-1025-4210)
@en
name
Giovanni Martinelli
@en
type
label
Giovanni Martinelli
@en
prefLabel
Giovanni Martinelli
@en
P31
P496
0000-0002-1025-4210